Adagene and Incyte Collaborate on Cancer Therapy

Adagene and Incyte are launching a clinical collaboration to evaluate Muzastotug (ADG126) in combination with Incyte's bispecific antibody (INCA33890). This Phase 1 study will focus on patients with microsatellite stable colorectal cancer, including those with liver metastases. The trial is expected to commence in 2026 and will be sponsored and funded by Incyte. This partnership aims to explore novel treatment combinations for advanced colorectal cancer, potentially offering new therapeutic options for patients with limited existing treatments.